

FIG. 1

CONTIG Sequence 4 (kilobase):





FIG. 2



BEST AVAILABLE COPY

FIG. 3





FIG. 4A

R217A WILD TYPE Mice (N = 7)




p < 0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

FIG. 4B

R217A WILD TYPE Mice (N = 7)



p < 0.05 (t-test: relative to vehicle-treated controls)


Treatment (100 mg/kg PO @ - 120 min)

+

+

FIG. 4C

R217A HETEROZYGOTE Mice (N = 7-8)




p < 0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

FIG. 4D

R217A HETEROZYGOTE Mice (N = 7-8)



p < 0.05 (t-test: relative to vehicle-treated controls)


Treatment (100 mg/kg PO @ - 120 min)

+

+

FIG. 4E


R217A HOMOZYGOTE Mice (N = 7)



Treatment (100 mg/kg PO @ - 120 min)


FIG. 4F

R217A HOMOZYGOTE Mice (N = 7)




Treatment (100 mg/kg PO @ - 120 min)

FIG. 5





* $p < 0.05$ (t-test: relative to wild type controls)

FIG. 6



BEST AVAILABLE COPY

+

FIG. 7A**FIG. 7B**

+

FIG. 8A




FIG. 8B




FIG. 9

